Tumor-intrinsic chromatin programs enforce immune evasion in glioblastoma - PubMed
6 hours ago
- #glioblastoma
- #OLIG2
- #immune evasion
- Immunotherapy has limited efficacy in glioblastoma (GBM) due to immune evasion and an immunosuppressive microenvironment.
- The transcription factor OLIG2 is identified as a central mediator of immune evasion in GBM.
- OLIG2 promotes GBM progression through effects on glioma stem-like cells (GSCs).
- OLIG2 epigenetically represses the chemokine CXCL10, limiting cytotoxic T cell infiltration.
- These findings explain immune resistance in GBM and suggest targeting tumor-intrinsic chromatin programs to improve immunotherapy responses.